• Home
  • About us
  • Team
    • Management team
    • Advisory Board
  • Portfolio companies
    • Exited investments
    • Current investments
  • News
  • Contact

News

Home / News

Allergan Acquires Gene Therapy Company RetroSense Therapeutics Adding First-In-Class Technology to Company's Innovative Eye Care Pipeline

08.09.2016

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and RetroSense Therapeutics LLC, a private, clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in patients suffering from blindness, today announced that Allergan has acquired substantially all of the assets of RetroSense in an all-cash transaction.

More

RetroSense Therapeutics Selected as one of MIT Technology Review’s 50 Smartest Companies of 2016

24.06.2016

The selection of RetroSense as one MIT Technology Review’s 50 Smartest Companies in 2016 highlights the technological significance of RetroSense’s novel therapy.

More

RetroSense Therapeutics Doses First Patient in Phase I/II Clinical Trial for Lead Compound RST-001

21.03.2016

Clinical trial to assess the safety and, potentially efficacy, of novel gene therapy application of optogenetics in patients with retinitis pigmentosa

More

RetroSense Therapeutics Raises $6 million in an Over-­Subscribed Series B Financing to Advance Clinical Development of Lead Product RST­‐001 for Retinitis Pigmentosa

16.11.2015

Patient recruitment underway for Phase I/II clinical study RetroSense Therapeutics, a privately­‐held, clinical-stage biopharmaceutical company, today announced that it has secured $6 million in a Series B financing to further investigate the use of gene therapy and optogenetics to restore vision.

More

Image Analysis Ltd. secures $5.2m from RBV Capital

25.05.2015

LONDON, United Kingdom, April 27, 2015 – Image Analysis Limited, a privately-held digital health software and services provider of medical imaging analysis in clinical trials and daily clinical practice, has completed a $5.2m venture financing with Danish Research Foundation (DRF) and RBV Capital.

More
Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11